Previous 10 | Next 10 |
CytoDyn (CYDY) has executed an exclusive supply and distribution agreement with Macleods Pharmaceuticals in India.This commercial agreement will enable Macleods to sell leronlimab in India following regulatory clearance. “We believe there is an immediate need for leronlimab i...
Macleods is one of the largest pharmaceutical companies in India with presence in over 140 countries VANCOUVER, Washington, May 13, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company"), a late-stage biotechnology company develo...
Drs. Pourhassan, Recknor, Seethamraju and Nicolas will appear in a one-hour segment beginning at 5:00 pm PT / 8:00 pm ET, Sunday, May 9 VANCOUVER, Washington, May 07, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company"), a la...
In 2019, CytoDyn touted initial approval of leronlimab as a blockbuster combination therapy for HIV. CytoDyn has encountered a long string of obstacles in presenting leronlimab to the FDA for its consideration. Leronlimab's current status in its quest for approval as combination t...
CytoDyn (CYDY) announces an agreement to partner with Academic Research Organization - Albert Einstein Israelite Hospital in São Paulo, Brazil for two COVID-19 trials. The COVID-19 trials in Brazil are intended to provide the regulatory authority, ANVISA, with the requisite data to consi...
Interim analysis for critically ill population will be conducted when enrollment reaches about 120 patients or 40% of the approximate 300 patients VANCOUVER, Washington, May 05, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Comp...
CytoDyn (CYDY) announces a comprehensive update on three continuing extension studies with leronlimab as a treatment for HIV. Clinical results from multiple trials show that Vyrologix can significantly reduce the viral burden in people infected with HIV.Moreover, a Phase 2 trial demonstrated ...
VANCOUVER, Washington, May 03, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company"), a late-stage biotechnology company developing Vyrologix™ (leronlimab-PRO 140), a CCR5 antagonist with the potential for multiple therapeutic in...
VANCOUVER, Washington, May 03, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (Vyrologix or PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indicat...
Following the successful conclusion of three clinical trials, approximately 120 patients continue treatment with leronlimab in extension arms VANCOUVER, Washington, May 03, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company")...
News, Short Squeeze, Breakout and More Instantly...
Terms of the settlement include $12,000,000 cash payment to CytoDyn and elimination of $14,000,000 accounts payable liability from the Company’s balance sheet VANCOUVER, Washington, July 09, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a bio...
VANCOUVER, Washington, June 27, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that its preclinical MASH study with SMC ...
VANCOUVER, Washington, May 28, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that Dr. Jacob P. Lalezari, Chief Executiv...